2型糖尿病患者应用西格列汀的短期疗效及影响因素

doi:10.6040/j.issn.1671-7554.0.2016.199

摘要/Abstract

摘要： 目的分析2型糖尿病患者应用西格列汀的短期疗效及其影响因素,为临床患者的选择及提高疗效提供依据。方法收集2012年9月至2014年6月住院并应用西格列汀的2型糖尿病患者86例病例资料。根据患者空腹C肽水平四分位数分为C肽水平最高组和C肽水平最低组,每组12例。采用多元线性逐步回归分析患者临床资料中影响血糖下降水平的因素。结果使用西格列汀后,C肽水平最高组与C肽水平最低组空腹血糖(FBG)下降值、餐后2 h血糖(2h-PBG)下降值及百分数差异无统计学意义(P>0.05)。糖化血红蛋白(HbA1c)是影响FBG下降值及下降百分数的独立因素;用药前2h-PBG水平是影响2h-PBG下降值及其下降百分数的独立因素。患者使用西格列汀后,最大日内血糖波动值较使用前减小且低血糖发生显著减少(P<0.05)。结论西格列汀可同时降低患者FBG和2h-PBG,且疗效相当;其对FBG和2h-PBG的疗效不完全依赖于C肽水平;可显著减少血糖波动和低血糖事件的发生。

关键词: 餐后2 h血糖, 2型糖尿病, 西格列汀, 空腹血糖

Abstract: Objective To analyze the factors that affect the efficacy of sitagliptin in the treatment of type 2 diabetic mellitus(T2DM)patients. Methods Clinical data of 86 T2DM patients who treated with sitagliptin during Sept.2012 and June 2014 were collected. According to the levels of fasting C peptide, the patients were divided into two groups: maximum C peptide group(n=12)and minimum C peptide group(n=12). Multiple line regression analysis was performed to analyze the factors that might affect the efficacy of sitagliptin. Results After administration of sitagliptin, there was no significant difference in the decrease of fasting blood glucose(FBG)and 2 h post prandial blood glucose(2h-PBG)between the maximum and minimum C peptide groups(P>0.05). Multiple line regression analysis showed that HbA1c was an independent factor that affected the decrease of FBG; baseline 2h-PBG level was an independent factor that affected the efficacy of sitagliptin on 2h-PBG. Sitagliptin significantly decreased glucose excursion(P<0.05), and reduced episodes of hypoglycemia. Conclusion Sitagliptin decreases both FBG and 2h-PBG. The efficacy of sitagliptin may not entirely depend on C peptide levels. Sitagliptin significantly decreases blood excursion and hypoglycemia.

Key words: Type 2 diabetes mellitus, Sitagliptin, Fasting blood glucose, 2 h post prandial blood glucose

中图分类号:

R574

彭力,强晔,赵蕙琛,陈诗鸿,姚伟东,刘元涛. 2型糖尿病患者应用西格列汀的短期疗效及影响因素[J]. 山东大学学报（医学版）, 2016, 54(8): 60-63.

PENG Li, QIANG Ye, ZHAO Huichen, CHEN Shihong, YAO Weidong, LIU Yuantao. Clinical studies on type 2 diabetic patients treated with sitagliptin[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(8): 60-63.

参考文献

[1] Nauck M, Stöckmann F, Ebert R, et al. Reduced incretin effect in type 2(non-insulin-dependent)diabetes[J]. Diabetologia, 1986, 29(1): 46-52.
[2] Abraham EJ, Leech CA, Lin JC, et al. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells[J]. Endocrinology, 2002, 143(8): 3152-3161.
[3] Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus[J]. Diabetologia, 2005, 48(6): 1168-1172.
[4] 叶潇, 张倩, 曹瑛, 等. 西格列汀与阿卡波糖治疗新诊断2型糖尿病患者的疗效比较[J]. 中国糖尿病杂志, 2012, 8(20): 619-621. YE Xiao, ZHANG Qian, CAO Ying, et al. Comparison of therapeutic effects of sitagliptin versus acarbose for newly-diagnosed T2DM patients[J]. Chin J Diabetes, 2012, 8(20): 619-621.
[5] Giuseppe D, Pietro DR, Elena F, et al. Sitagliptin added to previously taken antidiabetic agents on insulin resistance and lipid profile: a 2-year study evaluation[J]. Fund Clin Pharmacol, 2014, 28(2): 221-229
[6] Keiji Y. Efficacy of initial basal-supported oral therapy with sitagliptin in untreated type 2 diabetes[J]. Diabetes Ther, 2013, 4(2): 409-416.
[7] Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes[J]. Diabetes, 2006, 55(6): 1695-1704.
[8] Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats[J]. Diabetes, 2003, 52(3): 741-750.
[9] Yuan GY, Jia J, Zhang CL, et al. Safety and effcacy of sitagliptin in combination with transient continuous subcutaneous insulin infusion(CSII)therapy in patients with newly diagnosed type 2 diabetes[J]. Endocrine Journal, 2014, 61(5): 513-521.
[10] Lu J, Zang J, Li H. Impact of three oral antidiabetic drugs on markers of b-Cell function in patients with type 2 diabetes: A meta-analysis[J]. PLoS One, 8(10): e76713. doi:10.1371/journal.pone.0076713.
[11] Gerald HT. Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors[J]. World J Diabetes, 2014, 5(5): 636-650.
[12] Holst JJ. The physiology of glucagon-like peptide 1[J]. Physiol Rev, 2007, 87(4): 1409-1439.
[13] Urd K, Jens JH, Sten M. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual b-Cell function[J]. Diabetes, 2011, 60(5): 1599-1607.
[14] Behme MT, Dupré J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes[J]. BMC Endocr Disord, 2003, 3(1): 3.
[15] Creutzfeldt WO, Kleine N, Willms B, et al. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36)amide in type I diabetic patients[J]. Diabetes Care, 1996, 19(6): 580-586.
[16] Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitorsitagliptinas monotherapy on glycemic control in patients with type 2 diabetes[J]. Diabetes Care, 2006, 29(12): 2632-2637.
[17] Nauck MA, Heimesaat MM, Behle K, et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers[J]. J Clin Endocrinol Metab, 2002, 87(3): 1239-1246.
[18] PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe non-proliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study(PKC-DRS)multicenter randomized clinical trial[J]. Diabetes, 2005, 54(7): 2188-2197.

相关文章 15

[1]	孟晓梅,郝亚平,王亮,于晓,唐与晓. 血清Isthmin1、Gremlin2水平与2型糖尿病患者视网膜病变的相关性[J]. 山东大学学报 (医学版), 2025, 63(9): 102-107.
[2]	申路佳,逯天威,巩伟明,赵岩松,王淑康,袁中尚. 代谢风险评分在2型糖尿病人群心血管结局预测中的应用[J]. 山东大学学报 (医学版), 2025, 63(8): 69-78.
[3]	陈莹莹,王鲁,胡锡峰,朱高培,薛付忠. 基于贝叶斯网络的2型糖尿病患者并发脑卒中风险预测[J]. 山东大学学报 (医学版), 2025, 63(8): 94-102.
[4]	李金泉,高美芳,闫飞,董明. 136例2型糖尿病患者肌肉痉挛的发生频率及危险因素[J]. 山东大学学报 (医学版), 2023, 61(5): 20-24.
[5]	张天鑫,张婷,黄鑫,韩佳沂,王淑康. 氨基酸与2型糖尿病因果关系的孟德尔随机化分析[J]. 山东大学学报 (医学版), 2023, 61(5): 102-107.
[6]	韩梅,孟维静,陶子琨,杨希,徐雅琪,穆华夏,卜伟晓,王素珍,石福艳. 基于G-计算的高血压、抑郁在2型糖尿病与认知功能之间的因果多中介分析[J]. 山东大学学报 (医学版), 2023, 61(10): 101-108.
[7]	赵美茹,朱迪,刘淋,管庆波,张栩. 简易胰岛素抵抗指标与698例2型糖尿病患者发生高尿酸血症风险的关联[J]. 山东大学学报 (医学版), 2022, 60(12): 44-51.
[8]	于书卷,王美娟,陈丽,曹英娟,吕晓燕,刘雪燕,林鹏,颜景政. 老年2型糖尿病患者轻度认知功能障碍的影响因素[J]. 山东大学学报 (医学版), 2022, 60(11): 108-112.
[9]	吕丽,姜璐,陈诗鸿,庄向华,宋玉文,王殿辉,安文娟,李倩,潘喆. 210例绝经后2型糖尿病发生骨质疏松的相关因素[J]. 山东大学学报 (医学版), 2021, 59(7): 19-25.
[10]	郑凤杰,宋玉文,孙爱丽,潘喆,王殿辉,娄能俊,吕丽, 庄向华,陈诗鸿. 糖尿病周围神经病变与肌少症的关联性[J]. 山东大学学报 (医学版), 2021, 59(6): 38-44.
[11]	刘萍,宋玉文,王萍,田光伟,郑凤杰,吕丽,杜娇娇,张静,庄向华,陈诗鸿. 维生素D缺乏与2型糖尿病合并抑郁状态的相关性[J]. 山东大学学报 (医学版), 2021, 59(6): 51-56.
[12]	张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7-14.
[13]	王余余,高丽,陈少华. 94例2型糖尿病患者急性脑梗死后认知障碍与甲状腺功能的关联性[J]. 山东大学学报 (医学版), 2020, 58(5): 56-61.
[14]	金海燕,张炎,马小莉,韩羽,赵蕙琛,刘元涛,张玉超. MiR-122与miR-33a在2型糖尿病合并冠心病患者中的表达[J]. 山东大学学报 (医学版), 2020, 58(3): 94-98.
[15]	唐博,邵静,崔静,孙健平. 2型糖尿病发病与高密度脂蛋白关系的机制研究[J]. 山东大学学报 (医学版), 2020, 58(3): 99-106.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed